Breaking News

Tweet TWEET

Positive Clinical Data, Upcoming Presentations, and Completed Acquisitions - Research Report on Merck, Perrigo, Celgene, Cigna,

 Positive Clinical Data, Upcoming Presentations, and Completed Acquisitions -
   Research Report on Merck, Perrigo, Celgene, Cigna, and Boston Scientific

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck &
Co., Inc. (NYSE: MRK), Perrigo Company (NYSE: PRGO), Celgene Corporation
(NASDAQ: CELG), Cigna Corporation (NYSE: CI), and Boston Scientific
Corporation (NYSE: BSX). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Merck & Co., Inc. Research Report

On November 2, 2013, Merck & Co., Inc. (Merck) announced the presentation of
interim data from the ongoing C-WORTHY Study, a Phase II clinical trial
evaluating the efficacy and safety of an all-oral regimen combining once-daily
MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor,
and MK-8742, an investigational HCV NS5A replication complex inhibitor, with
or without twice-daily ribavirin, administered for 12 weeks to
treatment-naïve, non-cirrhotic patients with HCV genotype 1a and 1b infection.
According to the Company, the interim data show that the administration of
MK-5172 and MK-8742 in combination is associated with sustained virologic
response (lack of detectable and quantifiable HCV) 12 weeks following the end
of study therapy (SVR12). Dr. Eliav Barr, Vice President, Infectious Diseases,
Merck Research Laboratories, said, "These data provide further support that we
can advance these candidates, which are currently in Phase IIB clinical
development, into a broader evaluation in a diverse range of HCV patients."
The Full Research Report on Merck & Co., Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/430d_MRK]

--

Perrigo Company Research Report

On November 1, 2013, Perrigo Company (Perrigo) announced that it has started a
voluntary, nationwide product recall to the retail level of 18 batches of its
acetaminophen infant suspension liquid, 160 mg/5 mL, sold in 2 oz. and 4 oz.
bottles with syringes in a box under store brand products the Company listed
on its website. The Company said that it initiated a recall because of the
remote potential that a small number of packages might contain an oral dosing
syringe without dose markings. The Company added that the correct syringe
should have a white or yellow plunger with specific dose markings for 1.25 mL,
2.5 mL, 3.75 mL, and 5 mL. Further, Perrigo informed that if the product's
syringe has these dose markings, customers can continue to use them while
following labeled use instructions. Perrigo is conducting the recall with the
knowledge of the US Food and Drug Administration. The Full Research Report on
Perrigo Company - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4168_PRGO]

--

Celgene Corporation Research Report

On October 30, 2013, Celgene Corporation (Celgene) announced that on November
12, 2013, the Company's management will present at the Credit Suisse
Healthcare Conference in Phoenix, Arizona, at 4:30 p.m. ET. The Company added
that on December 2, 2013, it will present at the Deutsche Bank BioFEST
Conference in Boston, Massachusetts, at 9:00 a.m. ET. Lastly, Celgene reported
that on December 8, 2013, it will present at the American Society of
Hematology in New Orleans, Louisiana, at 9:30 p.m. ET. The Full Research
Report on Celgene Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7f47_CELG]

--

Cigna Corporation Research Report

On October 31, 2013, Cigna Corporation (Cigna) announced that Cigna Medicare
Advantage plans in Florida achieved five stars, the highest possible rating,
from the Centers for Medicare & Medicaid Services (CMS), making the Company
one of 11 five-star plans nationally and the only publicly traded Company to
achieve five-star rating for its Medicare Advantage business. According to the
Company, its Florida Medicare Advantage business serves more than 44,000
customers and includes Cigna-HealthSpring plan choices in Bay, Escambia and
Santa Rosa counties as well as Leon Medical Centers Health Plans by
Cigna-HealthSpring in Miami-Dade County, which serves customers with a
high-touch experience through state-of-the-art medical centers. Cigna further
reported that CMS evaluates more than 50 measures in nine categories from
medical outcomes data, information from health care providers and health
plans, as well as customer satisfaction surveys; among them are preventive
care, managing chronic diseases and customer experience. The Full Research
Report on Cigna Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7307_CI]

--

Boston Scientific Corporation Research Report

On November 1, 2013, Boston Scientific Corporation (Boston Scientific)
announced that it closed on its previously announced agreement to acquire Bard
EP, the electrophysiology (EP) business of C.R. Bard, Inc. (Bard). According
to Boston Scientific, this acquisition enables the Company to provide a
broader portfolio of EP tools, including solutions for cardiac catheter
ablations. Pete Sommerness, General Manager, Electrophysiology, Boston
Scientific, said, "We believe that the complementary capabilities that this
transaction brings, including expertise in capital equipment sales and
service, will enable us to offer more complete solutions to help
electrophysiologists diagnose and treat patients with cardiac arrhythmias."
The Company currently expects net impact of the transaction on adjusted EPS to
be immaterial in full-year 2013 and approximately accretive by $0.01 in
full-year 2014, and dilutive on a GAAP basis in both years as a result of
acquisition-related net charges and amortization, which will be determined
subsequent to the closing of this transaction. The Full Research Report on
Boston Scientific Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5640_BSX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)